United Therapeutics Chairperson & CEO Martine Rothblatt Executes Rule 10b5-1 Option Exercise and Sale
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
{"title": "United Therapeutics Corp (UTHR) - Insider Sale Filed", "color": 15158332, "fields": [{"name": "Insider", "value": "Martine A. Rothblatt (Chairperson & CEO)", "inline": true}, {"name": "Transaction Type", "value": "Option Exercise & Sale (10b5-1)", "inline": true}, {"name": "Shares Sold", "value": "9,500", "inline": true}, {"name": "Avg Sale Price", "value": "$501.59", "inline": true}, {"name": "Total Sale Value", "value": "$4,765,119.29", "inline": true}, {"name": "Remaining Trust Shares", "value": "324,443", "inline": true}]}
Comprehensive Analysis
Executive Summary
On September 15, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), executed an option exercise and sale of 9,500 shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The total disposition value was approximately $4.77 million at a weighted average price of $501.59 per share.
Transaction Details
- Option Exercise: Exercised 9,500 stock options with an exercise price of $117.76 per share.
- Open-Market Sales: Disposed of 9,500 shares across multiple tranches ranging from $499.24 to $505.04 per share.
- Net Proceeds (pre-tax/costs): ~$3.65 million above the $1.12 million exercise cost.
- Trading Plan: Transactions were conducted pursuant to a Rule 10b5-1 plan adopted on November 7, 2025.
Holdings Summary
Following the transactions, Dr. Rothblatt retains significant equity exposure across several trusts and direct holdings, including 324,443 shares in the executing family trust, 40,513 direct shares, 249,108 shares in spouse trusts, and 432,910 derivative stock options expiring in March 2027.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.